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STATE-OF-THE-ART OF GENE THERAPY FOR INHERITED 
RETINAL DYSTROPHIES
Inherited retinal dystrophies (IRDs) constitute a large group of
genetically and phenotypically heterogeneous diseases that are
characterized by progressive loss of photoreceptor cells leading loss
of vision. Many of the genes causing IRDs have now been identified,
and could ultimately be amenable to treatment by gene-replacement
therapies. There is also a robust proof of concept for gene transfer in
animal models of retinal dystrophy. Furthermore, three independent
clinical trials have shown the vision improvement in patients with an
early-onset autosomal recessive retinal dystrophy. In addition,
substantial progress has also been made in the development of
treatment strategies for autosomal dominant diseases: a promising
approach is the gene silencing using RNA-interference (RNAi).
INTRODUCTION
Review the recent progress in retinal gene therapy for IRDs:
• Candidate genes 
• Preclinical studies
• Current clinical trials  
OBJECTIVES
I have performed an exhaustive search and a posterior
selection of the latest original articles and reviews in the
field.
METHODOLOGY
1. Disease (heritance)
2. Target
3. therapeutic approach 
4. Preclinical studies 
- Vector
-Animal model
5. Clinical trial
- Vector 
- Phase: clinicaltrials.gov identifiers
- Preliminary data
1. MERTK-associated retinitis 
pigmentosa (AR)
2. RPE
3. Gene addition
4. Preclinical studies
- Lentivirus and AAV8
- Royal College of Surgeons 
rat
5. Clinical trial
- Lentivirus
- Phase  I/II:  NCT01482195
- Three patients have been 
treated showing no adverse 
effects 
1. Leber Congenital Amaurosis 2 (AR)
2. RPE
3. Gene addition
4. Preclinical studies
- AAV8
- Briard dogs  and Rpe65−/− mice
5. Clinical trial
- AAV2
- Phase  I/II :  NCT00481546, NCT00516477, NCT00643747
- Phase III: NCT00999609
- Long-term vision improvement. Re-administration of the vector in 
the contralateral eye is safe and efficacious.  
1. Stargardt disease (AR)
2. Photoreceptors
3. Gene addition
4. Preclinical studies
- EIAV lentivirus and 
“heterogeneous” AAV
- abca4-/- mice 
5. Clinical trial
- EIAV lentivirus
- Phase  I/II:  
NCT01367444
- No preliminary data 
available 
1. Leber Congenital 
Amaurosis  1 (AR)
2. Photoreceptors
3. Gene addition
4. Preclinical studies
- AAV2/8 and AAV5 
- Gucy2e-/- mice and 
GC1/GC2 double knock-
out (GCdko) mice
1. RHO-linked retinitis pigmentosa (AD)
2. Photoreceptors
3. The approach involves the use of two components: one 
that suppress both mutant and wild-type RHO alleles and 
another that provide a RHO gene replacement
4. Preclinical studies
- AAV2/5
- P347S mice
GENE THERAPY FOR INHERITED RETINAL DYSTROPHIES
The retina is one of the most promising target tissues for gene therapy.
Gene therapy will soon become a realistic treatment choice for many more retinal dystrophies.
The main challenge over the next years is to rescue the vision of more IRDs mouse models, to translate more of
the bench findings into clinical studies for more IRDs and to optimize treatments in patients already available.
CONCLUSIONS
Gene-based therapy is defined as the introduction, using a vector, of nucleic acids into cells with the intention of
altering gene expression to prevent, cease or reverse a pathological process.
In the following figure show the location of proteins whose genes are candidates for gene-based therapy. Most of
the candidate genes have protein products that are located in the outer segments (OS) of the photoreceptor cells
or in the retinal pigment epithelium (RPE). Five of these genes are examined in deeper detail. Abbreviations: ONL,
outer nuclear layer; AR, autosomal recessive; AD, autosomal dominant; EIAV, Equine Infectious Anemia Virus.
COLOR CODE
Biomedical Science Degree       2012/2013
Adeno-associated 
virus (AAV)
• Transduce
photorreceptors
and RPE
• Low 
immunogenicity
• Non pathogenic
Lentivirus
• Transduce RPE
• Non 
immunogenic
VECTORS
Schematics diagrams of the eye and the retina layers, and the sites of vector delivery. 
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